Corcept Therapeutics Inc
NASDAQ:CORT
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
21.1
60.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Corcept Therapeutics Inc
Corcept Therapeutics Inc
Capital Expenditures
Corcept Therapeutics Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Corcept Therapeutics Inc
NASDAQ:CORT
|
Capital Expenditures
-$2.1m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-26%
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Capital Expenditures
-$4.4B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-2%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Capital Expenditures
-$1.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-8%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Capital Expenditures
-$3.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-7%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Capital Expenditures
-$3.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Capital Expenditures
-$8.3B
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-18%
|
|
Corcept Therapeutics Inc
Glance View
Corcept Therapeutics Inc. is a biopharmaceutical company that has carved out a distinctive niche in the world of medicine by focusing on the development of drugs that modulate the effects of the hormone cortisol. Founded in 1998, the company is headquartered in Menlo Park, California. The real turning point for Corcept came when it developed mifepristone, branded as Korlym, approved by the FDA in 2012 for the treatment of Cushing's syndrome—a rare endocrine disorder characterized by excessive cortisol levels. Korlym works by mitigating the effects of excessive cortisol, providing relief from a range of debilitating symptoms. This first-in-class medication provided Corcept with a foothold in the industry, enabling it to build a sustainable revenue stream from a patient population with significant unmet medical needs. The business model of Corcept is primarily anchored in its innovative endocrinology portfolio, with a keen focus on expanding its therapeutic applications to other cortisol-related conditions. Beyond Korlym, the company’s pipeline includes an array of selective cortisol modulators aimed at exploring potential treatments for conditions such as antipsychotic-induced weight gain and various forms of cancer. This strategic orientation towards research and development is crucial for Corcept's growth, allowing it to leverage its expertise and proprietary technology to propel further success. Revenues are chiefly generated through the direct sale of Korlym in the United States, with ambitions to broaden its market reach as it seeks regulatory approvals for new indications and territories. This approach not only reinforces its commitment to considerable unmet needs in medicine but also positions Corcept as an influential force in the realm of cortisol modulation therapies.
See Also
What is Corcept Therapeutics Inc's Capital Expenditures?
Capital Expenditures
-2.1m
USD
Based on the financial report for Sep 30, 2024, Corcept Therapeutics Inc's Capital Expenditures amounts to -2.1m USD.
What is Corcept Therapeutics Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 10Y
-26%
Over the last year, the Capital Expenditures growth was -1 990%. The average annual Capital Expenditures growth rates for Corcept Therapeutics Inc have been -38% over the past three years , -14% over the past five years , and -26% over the past ten years .
You don't have any saved screeners yet
